Non‐serious adverse events · farmworkers
It is very uncertain whether summary of findings table ‐ Antibiotics changes non‐serious adverse events compared with other antibiotics (very low certainty).
1 finding from 1 review
Non‐serious adverse events · farmworkers, soldiers, and people in endemic areas
It is very uncertain whether summary of findings table ‐ Antibiotics changes non‐serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Non‐serious adverse events · people with chronic liver diseases
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Non‐serious adverse events · people with resectable cholangiocarcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events · people with hepatocellular carcinoma
1 finding from 1 review
Non‐serious adverse events · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1 finding from 1 review
Non‐serious adverse events · children with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events · adult patients with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events · cirrhotic participants with large ascites treated by paracentesis
It is very uncertain whether other plasma expanders changes non‐serious adverse events compared with albumin (very low certainty).
1 finding from 1 review
Non‐serious adverse events · cirrhotic participants with large ascites treated by paracentesis
It is very uncertain whether plasma expanders changes non‐serious adverse events compared with no plasma expanders (very low certainty).
1 finding from 1 review
Non‐serious adverse events · patients with covert or overt hepatic encephalopathy
It is very uncertain whether acetyl‐L‐carnitine changes non‐serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Non‐serious adverse events · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Non‐serious adverse events · adults with oesophageal varices
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events · adults with cirrhosis and gastroesophageal varices
It is very uncertain whether carvedilol changes non‐serious adverse events compared with traditional, non‐selective beta‐blockers (very low certainty).
1 finding from 1 review
Non‐serious adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether ursodeoxycholic acid changes non‐serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events considered non‐serious · people with leptospirosis
It is very uncertain whether summary of findings table ‐ Antibiotics changes adverse events considered non‐serious compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · liver transplant recipients
Normothermic machine perfusion (NMP) showed no clear difference in adverse events considered non‐serious compared with static cold storage (SCS) (moderate certainty).
1 finding from 1 review
Adverse events considered non‐serious · liver transplant recipients
1 finding from 1 review
Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).
1 finding from 1 review